{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:47:33Z","timestamp":1790682453906,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T00:00:00Z","timestamp":1630195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T00:00:00Z","timestamp":1630195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00415-021-10764-7","type":"journal-article","created":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T08:02:20Z","timestamp":1630224140000},"page":"1996-2003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4106-6482","authenticated-orcid":false,"given":"Hiroki","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Yokouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiji","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,29]]},"reference":[{"key":"10764_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"10764_CR2","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140:3128\u20133138","journal-title":"Brain"},{"key":"10764_CR3","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"SS Zamvil","year":"2015","unstructured":"Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2:e62","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10764_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jnnp-2019-321988","volume":"91","author":"J Liu","year":"2020","unstructured":"Liu J, Mori M, Sugimoto K, Uzawa A, Masuda H, Uchida T, Ohtani R, Kuwabara S (2020) Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. J Neurol Neurosurg Psychiatry 91:132\u2013139","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10764_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","volume":"89","author":"K Kaneko","year":"2018","unstructured":"Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, Nishiyama S, Takahashi T, Misu T, Kuroda H, Tanaka S, Nomura K, Hashimoto Y, Callegaro D, Steinman L, Fujihara K, Aoki M (2018) CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89:927\u2013936","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10764_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/brain\/awaa102","volume":"143","author":"Y Takai","year":"2020","unstructured":"Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, Nishida H, Komori T, Seki M, Komatsu T, Nakamagoe K, Ikeda T, Yoshida M, Takahashi T, Ono H, Nishiyama S, Kuroda H, Nakashima I, Suzuki H, Bradl M, Lassmann H, Fujihara K, Aoki M (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 143:1431\u20131446","journal-title":"Brain"},{"key":"10764_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lino AM, Misu T, Leite MI, Aoki M, Fujihara K (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474\u2013481","journal-title":"Neurology"},{"key":"10764_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, Waldman A, Soelberg K, Asgari N, Ringelstein M, Aktas O, Gross N, Buttmann M, Ach T, Ruprecht K, Paul F, Brandt AU (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm 13:282","journal-title":"J Neuroinflamm"},{"key":"10764_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10257-z","author":"S Siritho","year":"2020","unstructured":"Siritho S, Nopsopon T, Pongpirul K (2020) Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10257-z","journal-title":"J Neurol"},{"key":"10764_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","volume":"126","author":"H Ishikawa","year":"2019","unstructured":"Ishikawa H, Kezuka T, Shikishima K, Yamagami A, Hiraoka M, Chuman H, Nakamura M, Hoshi K, Goseki T, Mashimo K, Mimura O, Yoshitomi T, Tanaka K (2019) Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology 126:1385\u20131398","journal-title":"Ophthalmology"},{"key":"10764_CR11","doi-asserted-by":"publisher","first-page":"577021","DOI":"10.1016\/j.jneuroim.2019.577021","volume":"336","author":"K Sugimoto","year":"2019","unstructured":"Sugimoto K, Mori M, Liu J, Tanaka S, Kaneko K, Oji S, Takahashi T, Uzawa A, Uchida T, Masuda H, Ohtani R, Nomura K, Hiwasa T, Kuwabara S (2019) The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. J Neuroimmunol 336:577021","journal-title":"J Neuroimmunol"},{"key":"10764_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jns.2016.06.036","volume":"367","author":"H Masuda","year":"2016","unstructured":"Masuda H, Mori M, Uzawa A, Muto M, Uchida T, Ohtani R, Akiba R, Yokouchi H, Yamamoto S, Kuwabara S (2016) Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. J Neurol Sci 367:375\u2013379","journal-title":"J Neurol Sci"},{"key":"10764_CR13","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, Lotan I (2019) Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm 6:e572","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10764_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","volume":"25","author":"R Narayan","year":"2018","unstructured":"Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Paul F, Levy M (2018) MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 25:66\u201372","journal-title":"Mult Scler Relat Disord"},{"key":"10764_CR15","doi-asserted-by":"publisher","first-page":"104319","DOI":"10.1016\/j.neuint.2018.10.016","volume":"130","author":"T Akaishi","year":"2019","unstructured":"Akaishi T, Sato DK, Takahashi T, Nakashima I (2019) Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. Neurochem Int 130:104319","journal-title":"Neurochem Int"},{"key":"10764_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","volume":"19","author":"M Jury\u0144czyk","year":"2019","unstructured":"Jury\u0144czyk M, Jacob A, Fujihara K, Palace J (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol 19:187\u2013195","journal-title":"Pract Neurol"},{"key":"10764_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fneur.2018.00217","volume":"9","author":"GR Dos Passos","year":"2018","unstructured":"Dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, Sato DK (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:217","journal-title":"Front Neurol"},{"key":"10764_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","volume":"220","author":"MB Hassan","year":"2020","unstructured":"Hassan MB, Stern C, Flanagan EP, Pittock SJ, Kunchok A, Foster RC, Jitprapaikulsan J, Hodge DO, Bhatti MT, Chen JJ (2020) Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol 220:110\u2013114","journal-title":"Am J Ophthalmol"},{"key":"10764_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","volume":"139","author":"R H\u00f6ftberger","year":"2020","unstructured":"H\u00f6ftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, Joldic D, Pittock SJ, Tillema JM, Gorman M, Lassmann H, Lucchinetti CF (2020) The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 139:875\u2013892","journal-title":"Acta Neuropathol"},{"key":"10764_CR20","doi-asserted-by":"publisher","first-page":"117002","DOI":"10.1016\/j.jns.2020.117002","volume":"416","author":"A Kabanovski","year":"2020","unstructured":"Kabanovski A, Jeeva-Patel T, Margolin E (2020) Severe visual loss after one episode of anti-MOG optic neuritis. J Neurol Sci 416:117002","journal-title":"J Neurol Sci"},{"key":"10764_CR21","first-page":"205521732110068","volume":"7","author":"S Asseyer","year":"2021","unstructured":"Asseyer S, Masuda H, Mori M, Bellmann-Strobl J, Ruprecht K, Siebert N, Cooper G, Chien C, Duchow A, Schlie\u00dfeit J, Liu J, Sugimoto K, Uzawa A, Ohtani R, Paul F, Brandt AU, Kuwabara S, Zimmermann HG (2021) AQP4-IgG autoimmunity in Japan and Germany: differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 7:20552173211006864","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10764_CR22","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1177\/1352458519864928","volume":"26","author":"ES Sotirchos","year":"2019","unstructured":"Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang J, Ogbuokiri E, Cowley NJ, Pellegrini N, Murphy OC, Mealy MA, Prince JL, Levy M, Calabresi PA, Saidha S (2019) Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler J 26:1360","journal-title":"Mult Scler J"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10764-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10764-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10764-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T16:08:23Z","timestamp":1647965303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10764-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,29]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10764"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10764-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,29]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was granted by the ethics Committee of the Chiba University School of Medicine (No. 4011).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provide consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}